Suresh B Rangasamy Selected Research

RNS60

1/2020	RNS60, a physically-modified saline, inhibits glial activation, suppresses neuronal apoptosis and protects memory in a mouse model of traumatic brain injury.
1/2018	Increase in Mitochondrial Biogenesis in Neuronal Cells by RNS60, a Physically-Modified Saline, via Phosphatidylinositol 3-Kinase-Mediated Upregulation of PGC1α.
1/2018	Correction to: Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy.
5/2017	Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suresh B Rangasamy Research Topics

Disease

5	Parkinson Disease (Parkinson's Disease) 03/2022 - 01/2016
4	Inflammation (Inflammations) 03/2024 - 01/2017
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020 - 05/2017
3	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2024 - 01/2018
3	Multiple Sclerosis 01/2023 - 05/2017
3	Nonketotic Hyperglycinemia 03/2022 - 04/2021
3	Inborn Urea Cycle Disorders 03/2022 - 04/2021
2	Neuroinflammatory Diseases 04/2024 - 05/2019
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2023 - 01/2020
2	Alzheimer Disease (Alzheimer's Disease) 12/2021 - 01/2015
2	Disease Progression 05/2017 - 01/2017
1	Pain (Aches) 03/2024
1	Heartburn (Pyrosis) 03/2024
1	Huntington Disease (Huntington's Disease) 03/2024
1	Amyloid Plaque 01/2023
1	Parkinsonian Disorders (Parkinsonism) 03/2022
1	Brain Injuries (Brain Injury) 12/2021
1	HIV Infections (HIV Infection) 05/2019
1	Synucleinopathies 05/2019
1	Experimental Arthritis 10/2018
1	Demyelinating Diseases (Demyelinating Disease) 05/2017
1	Chronic Disease (Chronic Diseases) 05/2017

Drug/Important Bio-Agent (IBA)

4	Sodium Benzoate FDA Link 03/2022 - 01/2015
4	RNS60IBA 01/2020 - 05/2017
3	Chemokine CCL5IBA 05/2019 - 01/2016
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 03/2024 - 01/2019
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 03/2022 - 01/2017
1	benzyl cinnamateIBA 04/2024
1	Amyloid (Amyloid Fibrils)IBA 01/2023
1	Immunomodulating AgentsIBA 01/2023
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	Neuroprotective AgentsIBA 03/2022
1	glyceryl tribenzoateIBA 03/2022
1	Food Additives (Food Additive)IBA 03/2022
1	Interleukin-12 (IL 12)IBA 01/2020
1	Interleukin-23 (Interleukin 23)IBA 01/2020
1	Maraviroc FDA Link 05/2019
1	CCR5 Receptors (CCR5 Receptor)IBA 05/2019
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 01/2019
1	Dopamine (Intropin)FDA LinkGeneric 01/2019
1	Peptides (Polypeptides)IBA 10/2018
1	ChemokinesIBA 01/2017

Therapy/Procedure

5	Therapeutics 03/2024 - 05/2017
1	Neurosurgical Procedures 12/2021
1	Oral Administration 05/2019
1	Intraperitoneal Injections 05/2017